All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

No Link Between Race and Renal Toxicity in Treatment of NS-NSCLC

Nov 3, 2021
Nino Balanchivadze, MD, FACP
Video

Nino Balanchivadze, MD, FACP, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer in relation to the race of patients.

Nino Balanchivadze, MD, FACP, senior administrative fellow of the Hematology and Oncology Fellowship Program at Henry Ford Cancer Institute, discusses the results of an analysis investigating renal toxicity in patients with nonsquamous non–small cell lung cancer treated in the KEYNOTE-189 study (NCT02578680).

The retrospective analysis looked at acute kidney injury (AKI) as an adverse event of pemetrexed (Alimta) combined with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-189 clinical trial. Though Black Americans have previously been found to be at a higher risk of morbidity and mortality from chronic kidney disease (CKD), the study found no correlation between AKI in Black patients compared with White patients.

The study, recently presented during the 2021 European Society for Medical Oncology Annual Congress, analyzed a total of 134 patients, 33 of whom (24.6%) identified as non-Hispanic Black, and 101 (75.4%) who identified as non-Hispanic White. The mean age of patients was 66.5 years. Investigators observed that 8.1% of patients developed AKI, with a median time to development of 4.5 months.

Of the 10 patients who experienced AKI, 3 were Black and 7 were White (P = .57), showing no correlation between race and AKI development.

The median overall survival of all patients was 15.2 months. Black ethnicity was not associated with increased mortality in this patient population (HR, 1.21; P = .46), and development of AKI was also not associated with increased mortality (HR, 1.13; 95% CI, 0.45-2.86).

Other conditions such as hypertension, diabetes mellitus, cardiovascular disease, or CKD were not associated with AKI in these patients. However, patients with CKD were more likely to have a reduced glomerular filtration rate (GFR).

0:08 | We found we had a total of 134 patients that were included in the analysis. The mean age of patients was 66.5 years, and about 48.5% patients were men. A total of 33 patients, or 24.6% of our patients were non-Hispanic Black, and 75.4% of patients were non-Hispanic White. There were 10 patients who developed AKI and with the median time to development of kidney injury was 4.5 [months], with no margin of [patients of] black or white race with AKI. And the odds of developing AKI was not increased in patients with a history of hypertension, diabetes mellitus, cardiovascular disease, or CKD. We also found that a total of 17, or 13.4% of patients, had significantly reduced GFR, and patients that had a history of CKD were more likely to have reduced GFR.

Related Videos
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Related Content

KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma

September 25th 2023

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023

Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC

September 22nd 2023

Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15th 2020

Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

September 20th 2023

Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

September 19th 2023

KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma

September 25th 2023

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023

Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC

September 22nd 2023

Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15th 2020

Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

September 20th 2023

Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

September 19th 2023

KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma

September 25th 2023

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023

Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC

September 22nd 2023

Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15th 2020

Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

September 20th 2023

Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

September 19th 2023
Related Content
Advertisement

KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma

KRd-D Generates High MRD Negativity Rates in Smoldering Multiple Myeloma

September 25th 2023
Article

C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.

Read More


Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen


Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC

Pembrolizumab/Lenvatinib Shows No Survival Advantage in Metastatic, Nonsquamous NSCLC

September 22nd 2023
Article

The phase 3 LEAP-006 study of pembrolizumab plus lenvatinib and chemotherapy has missed its dual primary end points.

Read More


Individualizing Immunotherapy in Non–Small Cell Lung Cancer

Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15th 2020
Podcast

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

Listen


Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

Erdafitinib’s ‘Time to Shine’ in FGFR-Altered Urothelial Cancer

September 20th 2023
Article

In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.

Read More


Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

Trastuzumab Deruxtecan Revolutionizes Treatment in HER2+ Breast Cancer

September 19th 2023
Article

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, discusses the impact of trastuzumab deruxtecan, new developments, and unmet needs in the HER2-positive breast cancer space.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.